+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Histology and Cytology IVD Market Update, 2024

  • PDF Icon

    Report

  • 80 Pages
  • May 2024
  • Region: Global
  • Kalorama Information
  • ID: 5971388

This report provides a competitive analysis of the histology/cytology market from 2023 to 2028. Histology/cytology has been a mainstay of the pathological lab, providing information about cells, tissues and organs. A variety of diseases can be identified with a histopathological examination. Physicians rely on information from the pathologist as to whether there is cancer present or other disease. The physician bases their treatment and prognosis on the pathological information obtained. Technological advancements have increased the knowledge and understanding of the shape-function relationships within tissues and organs and their relationship to disease.

The industry has forged ahead with new technologies that offer increased accuracy and automated workflow. In the coming years, digital imaging, quantitative microscopy, precision microscopy, artificial intelligence and virtual histology will take the histology/cytology industry to the next level.

As discussed in the report, the histology market is a growing market with much potential. This report only looks at traditional histology. The histology report is segmented into five areas:

  • Traditional non-PAP Stains
  • PAP
  • In situ Hybridization
  • Immunohistochemistry
  • HPV

The histology report also examines and profiles five key market participants:

  • Agilent
  • Danaher Corporation
  • Hologic
  • Illumina
  • Roche Diagnostics

Scope and Methodology

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews, in-person interviews and email correspondence were the primary methods of gathering information. For the purpose of this study, the publisher conducted interviews with industry officials, consultants, healthcare providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers’ level. The market includes manufacturer tests. The base year for data was 2023. Data are provided for 2023 and 2028 with compound annual growth rates (CAGRs) for 2023 and 2028. Competitive analysis is provided for the top five participants in the market. Regional breakdowns are surveyed for the United States, Europe, Asia-Pacific and Rest of World for 2023. The forecasted market analysis for 2023-2028 was largely based on demographic trends, new developments, innovative technology and global expansion.

Table of Contents

CHAPTER 1: EXECUTIVE SUMMARY
  • INDUSTRY AT A GLANCE
  • SCOPE AND METHODOLOGY
  • SIZE AND GROWTH OF THE MARKET
    • Figure 1-1: Global Histology IVD Market, 2023-2028 ($ millions)
  • COMPETITIVE OUTLOOK
CHAPTER 2: MARKET OVERVIEW
  • OVERVIEW OF HISTOLOGY/CYTOLOGY
  • HISTOLOGY AND CANCER
  • ADVANCED ANALYSIS SOLUTIONS
    • Table 2-1: Selected Advanced Histology Techniques
  • LABORATORY DEVELOPED TESTS
  • AI AND HISTOLOGY
CHAPTER 3: MARKET SIZE AND GROWTH
  • MARKET SEGMENTS
    • Table 3-1: Global Histology/Cytology Sales, by Type (Pap Tests, In situ hybridization, Immunohistochemistry, Traditional non-Pap stains, HPV), 2023-2028 ($ millions)
    • Figure 3-1: Global Histology/Cytology IVD Market, 2023-2028 ($ millions)
    • Figure 3-2: Histology/Cytology Diagnostic Market Distribution, by Broad Test Category (Pap Tests, In situ hybridization, Immunohistochemistry, Traditional non-Pap stains, HPV), 2023 (%)
  • Traditional Tissue Stains
    • Table 3-2: Selected Vendors of Traditional Histology Stains
  • PAP Tests
    • Table 3-3: Primary and Secondary Prevention of Cervical Cancer, Screening Responses by Country, 2022 (last updated 2022-5-6)
  • Immunohistochemistry and In Situ Hybridization
    • Table 3-4: Selected in Situ Hybridization-based Tests
    • Table 3-5: Selected IHC Test Innovations
  • HPV
    • Figure 3-3: HPV Screening Market: HPV DNA and Pap Test Distribution of Sales, 2023
    • Table 3-6: Global HPV Molecular (DNA/RNA) Test Sales Distribution, by Region (North America, Europe, Asia Pacific, RoW), 2023 (%)
    • Table 3-7: Selected HPV Test Innovations
  • MARKET BY REGION
    • Table 3-8: Global Histology/Cytology Market, by Region (North America, Europe, Asia, RoW), 2023-2028 ($ millions)
    • Figure 3-4: Global Histology/Cytology Market, by Region (North America, Europe, Asia, RoW), 2023-2028 (%)
    • Table 3-9: Global Histology/Cytology Sales Distribution, by Region (North America, Europe, Asia Pacific, RoW), 2023 (%)
  • North America
    • Table 3-10: North America Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
    • Figure 3-5: North America Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
  • Europe
    • Table 3-11: Europe Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
    • Figure 3-6: Europe Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
  • Asia Pacific
    • Table 3-12: Asia Pacific Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
    • Figure 3-7: Asia Pacific Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
  • Rest of World (RoW)
    • Table 3-13: Rest of World (RoW) Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
    • Figure 3-8: Rest of World (RoW) Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
  • COMPETITIVE ANALYSIS
    • Table 3-14: Revenues of the Major Histology Companies, 2017-2023 ($ millions, estimated)
    • Table 3-15: Pathology Launches by Roche
  • THE COMMERCIAL OUTLOOK FOR HISTOLOGY
CHAPTER 4: MAJOR MARKET PARTICIPANTS
  • ABBOTT DIAGNOSTICS
    • Table 4-1: Abbott Corporate Summary
    • Table 4-2: Abbott Revenue History, 2017-2023 ($ million)
  • AGILENT
    • Table 4-3: Agilent Corporate Summary
    • Table 4-4: Agilent Diagnostic Revenues, 2017-2023 ($ millions)
    • Figure 4-1: Agilent Revenues, by Group, 2022-2023 ($ millions)
  • BECTON, DICKINSON AND COMPANY
    • Table 4-5: Becton Dickinson Corporate Summary
    • Table 4-6: BD Revenue History, 2017-2023 ($ million, FYE Sept 30)
  • BIOCARE MEDICAL
    • Table 4-7: Biocare Medical Corporate Summary
  • BIOGENEX
    • Table 4-8: BioGenex Corporate Summary
  • DANAHER CORPORATION
    • Table 4-9: Danaher Corporation Summary
    • Table 4-10: Danaher Revenue History, 2017-2023 ($ million, estimated)
    • Figure 4-2: Danaher Diagnostics (Recurring/Nonrecurring), Full Year 2022 and 2023 ($ millions)
  • HOLOGIC
    • Table 4-11: Hologic Corporate Summary
    • Table 4-12: Hologic Revenue History, 2017-2023 ($ million, estimated)
    • Figure 4-3: Hologic Diagnostic Product Revenues, FY 2022 and FY 2023 ($ million)
  • ILLUMINA, INC
    • Table 4-13: Illumina Corporate Summary
    • Table 4-14: Illumina Diagnostics Revenues, 2017-2023 ($ millions)
    • Figure 4-4: Illumina Diagnostic Revenues, 2022-2023 ($ millions)
  • MEDIMEAS
    • Table 4-15: Medimeas Corporate Summary
  • QIAGEN N.V.
    • Table 4-16: QIAGEN Corporate Summary
    • Table 4-17: QIAGEN Revenue History, 2017-2023 ($ million, estimated)
  • ROCHE DIAGNOSTIC (ROCHE TISSUE DIAGNOSTICS)
    • Table 4-18: Roche Diagnostic Corporate Summary
    • Table 4-19: Roche Revenue History ($ million, estimated)
    • Figure 4-5: Roche Diagnostic Performance, Full Year 2022 and 2023 (CHF Mn)
  • SYSMEX
    • Table 4-20: Sysmex Corporate Summary
    • Table 4-21: Sysmex Revenue History, 2017-2023 ($ million, estimated)
  • THERMO FISHER SCIENTIFIC
    • Table 4-22: Thermo Fisher Corporate Summary
    • Table 4-23: Thermo Fisher Revenue History, 2017-2023 ($ million, estimated)

Samples

Loading
LOADING...